Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
ViroMissile, Inc.
Replimune Inc.
Pfizer
Tizona Therapeutics, Inc
M.D. Anderson Cancer Center
AgonOx, Inc.
Novartis
University Health Network, Toronto
Petrov, Andrey
AstraZeneca
Guangzhou FineImmune Biotechnology Co., LTD.
Thomas Jefferson University
Columbia University
Revolution Medicines, Inc.
Novartis
Checkpoint Therapeutics, Inc.
ABM Therapeutics Corporation
Inhibrx Biosciences, Inc
National Cancer Institute (NCI)
Celldex Therapeutics
University of California, San Francisco
R-Pharm
AO GENERIUM
National Cancer Institute (NCI)
Fate Therapeutics
Cantargia AB
Prelude Therapeutics
Bristol-Myers Squibb
Quadriga Biosciences, Inc.
Provectus Pharmaceuticals
Revolution Medicines, Inc.
Imperial College London
Pfizer
Incyte Corporation
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
BioNTech SE
Asana BioSciences
Lumos Pharma
Celgene
National Institutes of Health Clinical Center (CC)
AstraZeneca
Santa Maria Biotherapeutics
OrienGene Biotechnology Ltd.
Shenzhen Second People's Hospital
BIND Therapeutics
SillaJen, Inc.
Northwestern University